YUCAIPA, Calif., July 22, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company has developed $2,500,000 worth of product inventory as a part of the initial strategic relationship with the Pacific Pearl Group and their commitment to assist Ingen Technologies with increased value.
"The distribution of the Company's flagship product -- Oxyview -- in China is an indication that Ingen Technologies recognizes the underserved, respiratory market, where COPD ranks first among the burdens of diseases in the country. Pacific Pearl Group is uniquely positioned to assist Ingen Technologies to assess potential bids from the domestic and international markets, in particular China, and we will simultaneously evaluate other viable strategies in order to deliver shareholder value," stated Reisa Jiang, founder and Chief Executive Officer of Pacific Pearl Group.
Pacific Pearl Group (Member FINRA/SIPC) is a China-focused investment bank dedicated to advising small- and micro-cap companies and privately-held firms. Headquartered in Pasadena, California, Pacific Pearl Group provides a broad array of financial and strategic advisory services to corporate clients including: mergers and acquisitions, private placements, proprietary market research and turnaround management.
The company has initiated the production of 100,000 Oxyview units , with an additional 60,000 Oxyview Nasal Cannula's being delivered in August-2009. The aggressive saturation advertising campaign scheduled in the Fall with COPD Digest, Medco Forum and several others, in combination with restructure and strengthening of the distribution network; Ingen anticipates better earnings than expected in the next few months to come. Despite the fierce cuts in Medicare and low priced cannuals being sold today without an oxyview attached, experts predict strong customer purchase support of the new Oxyview Nasal Cannula simply based on patient demand, and as a means to improve oxygen therapy and an overall savings as a result in a decrease of service calls.
"Ingen is now positioned to create strong revenues, earnings and shareholder profits," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
http://www.pacpearl.com/
About Ingen Technologies / Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment